Plasma oxytocin levels predict social cue recognition in individuals with schizophrenia

Schizophrenia Research

Volumn 162, Issue 1-3, 2015, Pages 47-51

  Strauss, Gregory P ^a   Keller, William R ^b   Koenig, James I ^b   Gold, James M ^b   Frost, Katherine H ^a   Buchanan, Robert W ^b  

^a BINGHAMTON UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Interpersonal; Oxytocin; Psychosis; Social cognition

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLONAZEPAM; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; OLANZAPINE; OXYTOCIN; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE;

ADULT; ARTICLE; BEHAVIOR ASSESSMENT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; OXYTOCIN BLOOD LEVEL; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIAL COGNITION; SOCIAL CUE RECOGNITION TEST; SOCIAL INTERACTION; VIDEORECORDING; ASSOCIATION; BLOOD; HUMAN RELATION; PERCEPTION; PSYCHOLOGIC TEST; PSYCHOLOGICAL INTERVIEW; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOTIC DISORDERS;

ADULT; CUES; FEMALE; HUMANS; INTERPERSONAL RELATIONS; INTERVIEW, PSYCHOLOGICAL; MALE; OXYTOCIN; PSYCHIATRIC STATUS RATING SCALES; PSYCHOLOGICAL TESTS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL PERCEPTION;

EID: 84923231128     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.01.034     Document Type: Article

References (42)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, Author, Washington, DC. 4th ed., text rev.
2. Averbeck B.B., Bobin T., Evans S., Shergill S.S. Emotion recognition and oxytocin in patients with schizophrenia. Psychol. Med. 2012, 42(2):259-266.
3. Beckmann H., Lang R.E., Gattaz W.F. Vasopressin-oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls. Psychoneuroendocrinology 1985, 10(2):187-191.
4. Carter C.S., Pournajafi-Nazarloo H., Kramer K.M., Ziegler T.E., White-Traut R., Bello D., Schwertz D. Oxytocin: behavioral associations and potential as a salivary biomarker. Ann. N. Y. Acad. Sci. 2007, 1098:312-322.
5. Corrigan P.W., Green M.F. Schizophrenic patients' sensitivity to social cues; the role of abstraction. Am. J. Psychiatry 1993, 150:589-594.
6. Couture S.M., Penn D.L., Roberts D.L. The functional significance of social cognition in schizophrenia: a review. Schizophr. Bull. 2006, 32(suppl 1):S44-S63.
7. Dantzer R., Tanzi A., Bluthe R.M. Cerebral lateralization of olfactory-mediated affective processes in rats. Behav. Brain Res. 1990, 40(1):53-60.
8. Davis M.C., Lee J., Horan W.P., Clarke A.D., McGee M.R., Green M.F., Marder S.R. Effects of single dose intranasal oxytocin on social cognition in schizophrenia. Schizophr. Res. 2013, 147(2-3):393-397.
9. Davis M.C., Green M.F., Lee J., Horan W.P., Senturk D., Clarke A.D., Marder S.R. Oxytocin-augmented social cognitive skills training in schizophrenia. Neuropsychopharmacology 2014, 39(9):2070-2077.
10. Dickinson C., Keverne E.B. Importance of noradrenergic mechanisms in the olfactory bulbs for the maternal behavior of mice. Physiol. Behav. 1988, 43:313-316.
11. Dluzen D.E., Muraoka S., Landgraf R. Olfactory bulb norepinephrine depletion abolishes vasopressin and oxytocin preservation of social recognition responses in rats. Neurosci. Lett. 1998, 254(3):161-164.
12. Feifel D., Macdonald K., Nguyen A., Cobb P., Warlan H., Galangue B., Minassian A., Becker O., Cooper J., Perry W., Lefebvre M., Gonzales J., Hadley A. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol. Psychiatry 2010, 68(7):678-680.
13. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structural Clinical Interview for DSM-IV Axis 1 Disorders (SCID-IV). New York State Psychiatric Insititute 1997, Biometrics Research, New York.
14. Fischer-Shofty M., Brune M., Ebert A., Shefet D., Levkovitz Y., Shamay-Tsoory S.G. Improving social perception in schizophrenia: the role of oxytocin. Schizophr. Res. 2013, 146(1-3):357-362.
15. Fischer-Shofty M., Shamay-Tsoory S.G., Levkovitz Y. Characterization of the effects of oxytocin on fear recognition in patients with schizophrenia and in healthy controls. Front. Neurosci. 2013, 7:127.
16. Gibson C.M., Penn D.L., Smedley K.L., Leserman J., Elliott T., Pedersen C.A. A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia. Schizophr. Res. 2014, 156(2-3):261-265.
17. Goldman M., Marlow-O'Connor M., Torres I., Carter C.S. Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophr. Res. 2008, 98(1-3):247-255.
18. Goldman M.B., Gomes A.M., Carter C.S., Lee R. Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia. Psychopharmacology (Berl) 2011, 216(1):101-110.
19. Green M.F., Penn D.L., Bentall R., Carpenter W.T., Gaebel W., Gur R.C., Kring A.M., Park S., Silverstein S.M., Heinssen R. Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr. Bull. 2008, 34(6):1211-1220.
20. Hawk A.B., Carpenter W.T., Strauss J.S. Diagnostic criteria and five-year outcome in schizophrenia. A report from the International Pilot Study of schizophrenia. Arch. Gen. Psychiatry 1975, 32(3):343-347.
21. Horan W.P., Green M.F., DeGroot M., Fiske A., Hellemann G., Kee K., Kern R.S., Lee J., Sergi M.J., Subotnik K.L., Sugar C.A., Ventura J., Nuechterlein K.H. Social cognition in schizophrenia, Part 2: 12-month stability and prediction of functional outcome in first-episode patients. Schizophr. Bull. 2012, 38(4):865-872.
22. Horta de Macedo L.R., Zuardi A.W., Machado-de-Sousa J.P., Chagas M.H., Hallak J.E. Oxytocin does not improve performance of patients with schizophrenia and healthy volunteers in a facial emotion matching task. Psychiatry Res. 2014, 220(1-2):125-128.
23. Keri S., Kiss I., Kelemen O. Sharing secrets: oxytocin and trust in schizophrenia. Soc. Neurosci. 2009, 4(4):287-293.
24. Kirkpatrick B., Strauss G.P., Nguyen L., Fischer B.A., Daniel D.G., Cienfuegos A., Marder S.R. The brief negative symptom scale: psychometric properties. Schizophr. Bull. 2011, 37(2):300-305.
25. Kiss A., Bundzikova J., Pirnik Z., Mikkelsen J.D. Different antipsychotics elicit different effects on magnocellular oxytocinergic and vasopressinergic neurons as revealed by Fos immunohistochemistry. J. Neurosci. Res. 2010, 88(3):677-685.
26. Lee M.R., Wehring H.J., McMahon R.P., Linthicum J., Cascella N., Liu F., Bellack A., Buchanan R.W., Strauss G.P., Contoreggi C., Kelly D.L. Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study. Schizophr. Res. 2013, 145(1-3):110-115.
27. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol. Rep. 1962, 10:799-812.
28. Pedersen C.A., Gibson C.M., Rau S.W., Salimi K., Smedley K.L., Casey R.L., Leserman J., Jarskog L.F., Penn D.L. Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr. Res. 2011, 132(1):50-53.
29. Pfohl B.M., Blum N., Zimmerman M. Structured Interview for DSM-IV Personality 1997, American Psychiatric Publishing, Inc. 1st ed.
30. Roberts D.L., Penn D.L., Corrigan P., Lipkovich I., Kinon B., Black R.A. Antipsychotic medication and social cue recognition in chronic schizophrenia. Psychiatry Res. 2010, 178(1):46-50.
31. Rubin L.H., Carter C.S., Drogos L., Pournajafi-Nazarloo H., Sweeney J.A., Maki P.M. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr. Res. 2010, 124(1-3):13-21.
32. Rubin L.H., Carter C.S., Drogos L., Jamadar R., Pournajafi-Nazarloo H., Sweeney J.A., Maki P.M. Sex-specific associations between peripheral oxytocin and emotion perception in schizophrenia. Schizophr. Res. 2011, 130(1-3):266-270.
33. Rubin L.H., Carter C.S., Bishop J.R., Pournajafi-Nazarloo H., Harris M.S., Hill S.K., Reilly J.L., Sweeney J.A. Peripheral vasopressin but not oxytocin relates to severity of acute psychosis in women with acutely-ill untreated first-episode psychosis. Schizophr. Res. 2013, 146(1-3):138-143.
34. Rubin L.H., Carter C.S., Bishop J.R., Pournajafi-Nazarloo H., Drogos L.L., Hill S.K., Ruocco A.C., Keedy S.K., Reilly J.L., Keshavan M.S., Pearlson G.D., Tamminga C.A., Gershon E.S., Sweeney J.A. Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders. Schizophr. Bull. 2014, 40(6):1374-1384.
35. Sergi M.J., Rassovsky Y., Widmark C., Reist C., Erhart S., Braff D.L., Marder S.R., Green M.F. Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. Schizophr. Res. 2007, 90(1-3):316-324.
36. Strauss G.P., Hong L.E., Gold J.M., Buchanan R.W., McMahon R.P., Keller W.R., Fischer B.A., Catalano L.T., Culbreth A.J., Carpenter W.T., Kirkpatrick B. Factor structure of the Brief Negative Symptom Scale. Schizophr. Res. 2012, 142(1-3):96-98.
37. Strauss G.P., Keller W.R., Buchanan R.W., Gold J.M., Fischer B.A., McMahon R.P., Catalano L.T., Culbreth A.J., Carpenter W.T., Kirkpatrick B. Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale. Schizophr. Res. 2012, 142(1-3):88-92.
38. Strauss G.P., Keller W.R., Koenig J.I., Gold J.M., Ossenfort K.L., Buchanan R.W. Plasma oxytocin levels predict olfactory identification and negative symptoms in individuals with schizophrenia. Schizophr. Res. 2015, 162(1-3):57-61.
39. Wacker D.W., Ludwig M. Vasopressin, oxytocin, and social order recognition. Hormon. and Behav. 2012, 61(3):259-265.
40. Walss-Bass C., Fernandes J.M., Roberts D.L., Service H., Velligan D. Differential correlations between plasma oxytocin and social cognitive capacity and bias in schizophrenia. Schizophr. Res. 2013, 147(2-3):387-392.
41. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003, 64(6):663-667.
42. Woolley J.D., Chuang B., Lam O., Lai W., O'Donovan A., Rankin K.P., Mathalon D.H., Vinogradov S. Oxytocin administration enhances controlled social cognition in patients with schizophrenia. Psychoneuroendocrinology 2014, 47:116-125.